All the news Showing 4 of 4 articles from: Pharmaceutical industryGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NHS England seeks drug price cuts to eliminate hepatitis C by 2025 Keith Alcorn / 30 January 2018 NHS England announced this week that it aims to eliminate hepatitis C by 2025 – if it can negotiate 'best value for money' deals with the pharmaceutical industry in a new round ... Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows Keith Alcorn / 27 July 2017 HIV, hepatitis B and C and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College, London, reported ... France to provide universal access to hepatitis C treatment Keith Alcorn / 01 June 2016 France will provide access to hepatitis C treatment with direct-acting antivirals to everyone diagnosed with hepatitis C from September 2016, and will begin to provide treatment to everyone with stage 2 fibrosis immediately, ... Sofosbuvir/daclatasvir combination could be produced for $200 per cure Keith Alcorn / 14 December 2015 Month-by-month tracking of the prices paid in India for the chemicals used to make hepatitis C direct-acting antivirals shows that it is now possible to make and sell a combination of drugs ... ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive